Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Toxic Reactions: Overview01:26

Toxic Reactions: Overview

4.3K
When toxic substances penetrate the human body, they disseminate to various tissues, undergoing metabolic changes. This process yields reactive metabolites that may covalently bind with specific target molecules, resulting in toxicity.
Toxicity falls into two primary categories: local and systemic.
Local toxicity appears at the exposure site, such as protein denaturation caused by caustic substances.
In contrast, systemic toxicity requires the toxic agent's absorption and distribution,...
4.3K
Drug Toxicity: Overview01:00

Drug Toxicity: Overview

313
Drug toxicity quantifies the harm a compound causes to an organism, varying by dose and potentially impacting whole systems or specific organs like the liver. Toxic reactions may arise from venomous insect or spider bites, with effects ranging from mild symptoms to severe outcomes such as brain damage or death. Common forms of acute poisoning include ethanol intoxication and overdose of pain or fever medications, with substances like GHB and heroin being particularly lethal at doses close to...
313
Drug Toxicity: Risk factors01:24

Drug Toxicity: Risk factors

248
Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
248
Drug Toxicity: Dose-Dependent Reactions01:24

Drug Toxicity: Dose-Dependent Reactions

245
Drug toxicities can be stratified into pharmacological, pathological, or genotoxic based on their mechanisms. The incidence and severity of these toxicities generally increase with the drug's concentration in the body and exposure time.Pharmacological toxicity is evident when the therapeutic effects of drugs overshoot into adverse reactions in a predictable, dose-dependent manner. Central nervous system (CNS) depression from barbiturates is a classic example, with effects escalating from...
245
Toxicokinetics: Overview01:21

Toxicokinetics: Overview

330
Studies that assess how a drug is absorbed, distributed, metabolized, and excreted (ADME) at toxic doses are termed toxicokinetics. Understanding toxicokinetics helps predict adverse drug reactions (ADRs) and manage toxicity in humans.Toxicokinetics differs from pharmacokinetics mainly in the dose levels studied, with toxicokinetics focusing on higher toxic doses. The kinetics at these levels can be non-linear due to altered physiological processes. Toxicodynamics examines the relationship...
330
Toxicity Testing in Animals01:23

Toxicity Testing in Animals

222
Toxicity tests in animals are grounded on two main assumptions: first, the effects observed in laboratory animals can be extrapolated to humans, especially when adjusted for body surface area; second, high-dose exposure in animals is essential to identify potential human hazards from lower doses. This is based on the quantal dose-response concept, which faces the challenge of extrapolating results from relatively few test animals to much larger human populations. For example, a 0.01% incidence...
222

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pediatric chemotherapy.

Pediatric annals·2014
Same author

Old man river. The flow of pediatric oncology.

Hematology/oncology clinics of North America·2001
Same author

Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group phase II study.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2001
Same author

Low-stage medulloblastoma: final analysis of trial comparing standard-dose with reduced-dose neuraxis irradiation.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2000
Same author

Acute lymphoblastic leukemia with the (8;14)(q24;q32) translocation and FAB L3 morphology associated with a B-precursor immunophenotype: the Pediatric Oncology Group experience.

Leukemia·1999
Same author

Phase I study of topotecan in combination with cyclophosphamide in pediatric patients with malignant solid tumors: a Pediatric Oncology Group Study.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·1998

Related Experiment Video

Updated: May 5, 2026

Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity
07:42

Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity

Published on: April 26, 2012

18.1K

Evaluation of toxicity: clinical issues

T J Vietti

    Cancer Treatment Reports
    |February 1, 1980
    PubMed
    Summary

    This review examines toxicity criteria in cooperative cancer groups, emphasizing the need for better quality of life assessments and standardized toxicity documentation in therapeutic protocols.

    Area of Science:

    • Oncology
    • Clinical Trials
    • Pharmacovigilance

    Background:

    • Toxicity criteria are crucial for managing cancer therapies.
    • Current criteria vary among major cooperative groups.
    • Assessing patient quality of life during and after treatment is often overlooked.

    Purpose of the Study:

    • To review and discuss toxicity criteria used by major cooperative groups.
    • To highlight the need for standardized toxicity evaluation and quality of life assessment.
    • To emphasize the importance of incorporating toxicity data into therapeutic protocols.

    Main Methods:

    • Review of toxicity criteria from three major cooperative groups.
    • Discussion of the definition of acceptable toxicity based on disease extent and therapy availability.

    More Related Videos

    High Content Screening Analysis to Evaluate the Toxicological Effects of Harmful and Potentially Harmful Constituents HPHC
    11:38

    High Content Screening Analysis to Evaluate the Toxicological Effects of Harmful and Potentially Harmful Constituents HPHC

    Published on: May 10, 2016

    12.4K
    Accessing the Cytotoxicity and Cell Response to Biomaterials
    09:46

    Accessing the Cytotoxicity and Cell Response to Biomaterials

    Published on: July 8, 2021

    4.2K

    Related Experiment Videos

    Last Updated: May 5, 2026

    Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity
    07:42

    Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity

    Published on: April 26, 2012

    18.1K
    High Content Screening Analysis to Evaluate the Toxicological Effects of Harmful and Potentially Harmful Constituents HPHC
    11:38

    High Content Screening Analysis to Evaluate the Toxicological Effects of Harmful and Potentially Harmful Constituents HPHC

    Published on: May 10, 2016

    12.4K
    Accessing the Cytotoxicity and Cell Response to Biomaterials
    09:46

    Accessing the Cytotoxicity and Cell Response to Biomaterials

    Published on: July 8, 2021

    4.2K
  • Analysis of existing early warning signals for toxicity.

    • Main Results:

    • Significant variability exists in toxicity criteria among cooperative groups.
    • Adequate early warning signals exist for some toxicities, but not all.
    • Systematic evaluation of patient quality of life during and after therapy has been historically lacking.
    • Long-term pathophysiologic changes are beginning to be assessed.

    Conclusions:

    • Therapeutic protocols must include comprehensive toxicity information, modification criteria, and documentation schedules.
    • Development of therapeutic regimens should balance disease control with minimal impact on quality of life.
    • Further research is needed to establish satisfactory criteria for all forms of toxicity and to systematically evaluate quality of life.